This study assesses the cost-effectiveness of vaccination against herpes zoster (HZ) and postherpetic neuralgia in France, using a published Markov model. The cost-effectiveness of vaccinating individuals aged from 65 years or between 70 and 79 years was evaluated over their lifetime, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol five-dimension questionnaire) utilities from the literature. HZ vaccination was highly cost effective in both populations. Incremental cost-effective ratios were estimated between €9513 and 12,304 per quality-adjusted life year gained, corresponding to €2240-2651 per HZ case avoided and €3539-4395 per postherpetic neuralgia case avoided. In addition to epidemiological and clinical evidence, economic evidence also supports the implementation of HZ vaccination in France.
Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis
프랑스에서 대상포진 및 후대상포진 신경통에 대한 예방접종: 비용-효과성 분석
[Category] 대상포진, 두창, 수두, 홍역,
Pubmed URL [DOI] 10.1586/erp.13.19
[Source] pubmed
All Keywords